Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Liquidia Corp reported Q2 2026 revenue of $171.68M and diluted EPS of $0.74, a significant increase from the prior year's $8.84M revenue and -$0.49 EPS. This growth is attributed to the commercial launch of YUTREPIA in June 2025. The company continues its profit-share promotion with Sandoz for Treprostinil Injection, though pump availability limits uptake. R&D spending increased to advance L606 programs and new indications for YUTREPIA. Manufacturing agreements with Lonza and LGM ensure commercial supply.
Liquidia Corp reported results for the quarter ended 2026 with revenue of $171.68M and diluted EPS of $0.74, versus $8.84M revenue and ($0.49) EPS in the prior-year quarter, reflecting a material commercial ramp following the June 2025 launch of YUTREPIA.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $171.68M | $8.84M | 1842.7% |
| Net income² | $74.72M | ($41.58M) | 279.7% |
| Diluted EPS³ | $0.74 | ($0.49) | 251% |
¹ Reported as “Total revenue”. ² Reported as “Net income (loss) and comprehensive income (loss)”. ³ Reported as “Net income (loss) per common share, diluted”.
Business Highlights
- YUTREPIA commercial launch (June 2025) drove the large sequential and year-over-year revenue increase, supported by targeted field force and patient support programs.
- Continued profit-share promotion with Sandoz for Treprostinil Injection; pump availability is limiting subcutaneous patient uptake.
- R&D spending increased to advance L606 programs and potential additional indications for YUTREPIA, including PH-COPD, IPF, PPF and SSc-RP.
- Manufacturing and supply agreements with Lonza and LGM are in place, and non-cancelable manufacturing commitments support commercial supply.
Original SEC Filing: Liquidia Corp [ LQDA ] - 10-Q - Aug. 12, 2026